Petros Pharmaceuticals (PTPI)
OTHER OTC:PTPI
Want to see PTPI full AI Analyst Report?
Total Valuation
Petros Pharmaceuticals has a market cap or net worth of $305.08K. The enterprise value is -$5.14B.
Market Cap$305.08K
Enterprise Value-$5.14B
Share Statistics
Petros Pharmaceuticals has 42,372,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,372,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Petros Pharmaceuticals’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is 68.75%.
Return on Equity (ROE)0.67
Return on Assets (ROA)0.37
Return on Invested Capital (ROIC)68.75%
Return on Capital Employed (ROCE)-1.62
Revenue Per Employee0.00
Profits Per Employee106.31M
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Petros Pharmaceuticals is <0.1. Petros Pharmaceuticals’s PEG ratio is >-0.00001.
PE Ratio<0.1
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.00001
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 0.00 and earned 1.91B in profits. Earnings per share was 6.82.
Revenue0.00
Gross Profit0.00
Operating Income-4.64B
Pretax Income-4.50B
Net Income1.91B
EBITDA-4.64M
Earnings Per Share (EPS)6.82
Cash Flow
In the last 12 months, operating cash flow was -4.75B and capital expenditures 0.00, giving a free cash flow of -4.75B billion.
Operating Cash Flow-4.75B
Free Cash Flow-4.75B
Free Cash Flow per Share-112.04
Dividends & Yields
Petros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change-95.24%
50-Day Moving Average0.02
200-Day Moving Average0.36
Relative Strength Index (RSI)0.38
Average Volume (3m)352.83K
Important Dates
Petros Pharmaceuticals upcoming earnings date is Nov 14, 2023, Before Open (Confirmed).
Last Earnings DateAug 15, 2023
Next Earnings DateNov 14, 2023
Ex-Dividend Date―
Financial Position
Petros Pharmaceuticals as a current ratio of 2.25, with Debt / Equity ratio of 0.00%
Current Ratio2.25
Quick Ratio2.25
Debt to Market Cap0.00
Net Debt to EBITDA1.11K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Petros Pharmaceuticals has paid -6.41B in taxes.
Income Tax-6.41B
Effective Tax Rate1.43
Enterprise Valuation
Petros Pharmaceuticals EV to EBITDA ratio is 1.11K, with an EV/FCF ratio of 1.08.
EV to Sales0.00
EV to EBITDA1.11K
EV to Free Cash Flow1.08
EV to Operating Cash Flow1.08
Balance Sheet
Petros Pharmaceuticals has $5.14B in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.14B billion.
Cash & Marketable Securities$5.14B
Total Debt$0.00
Net Cash$5.14B
Net Cash Per Share$121.23
Tangible Book Value Per Share$10.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Petros Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast87.92%